CAR T-cell Therapy Shines In ALL; Safety Fix Highlighted At ASH
This article was originally published in The Pink Sheet Daily
Emerging data for the immunotherapy class continues to impress, and investigators at the American Society of Hematology report success with managing the cytokine-release syndrome side effects.
You may also be interested in...
Acute Lymphoblastic Leukemia Poised To Be First, Fast Driver Of CAR Immunotherapy
Given high complete response rates in early studies showcased at the American Society of Hematology’s recent annual meeting, acute lymphoblastic leukemia is a likely launch indication for chimeric antigen receptor immunotherapy. But while the results in B-cell malignancies are very promising so far, autologous CAR therapies are complex, and toxicities need to be carefully managed.
Novartis/Penn To Research Chimeric Antigen Receptor Immunotherapies
The Anglo/Swiss pharma will work with University of Pennsylvania researchers to discover, develop and commercialize CAR immunotherapy drugs for cancer, while also establishing a joint R&D facility at the Philadelphia campus.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.